Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 659

5.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
6.

Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine.

Entsuah R, Gorman JM.

J Psychiatr Res. 2002 May-Jun;36(3):111-8.

PMID:
11886688
7.
8.
9.

Venlafaxine extended-release: a review of its use in the management of major depression.

Wellington K, Perry CM.

CNS Drugs. 2001;15(8):643-69. Review.

PMID:
11524036
10.

Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.

Shelton C, Entsuah R, Padmanabhan SK, Vinall PE.

Int Clin Psychopharmacol. 2005 Jul;20(4):233-8.

PMID:
15933485
11.

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.

Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT.

J Clin Psychiatry. 2007 Aug;68(8):1246-56.

PMID:
17854250
12.

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.

Davidson JR, DuPont RL, Hedges D, Haskins JT.

J Clin Psychiatry. 1999 Aug;60(8):528-35.

PMID:
10485635
13.
14.

Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.

J Psychopharmacol. 2009 Jul;23(5):531-8. doi: 10.1177/0269881108089602. Epub 2008 Jul 17.

PMID:
18635695
15.

A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.

Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT.

J Clin Psychiatry. 1998 Mar;59(3):116-22.

PMID:
9541154
16.

Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.

Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G.

Int Clin Psychopharmacol. 2004 Nov;19(6):331-6.

PMID:
15486518
17.

Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.

Feighner JP, Entsuah AR, McPherson MK.

J Affect Disord. 1998 Jan;47(1-3):55-62.

PMID:
9476744
18.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
19.
20.

Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.

Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.

Depress Anxiety. 2002;16(1):4-13.

PMID:
12203668
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk